Synthetic Microchromosome vector delivery systems

Drug Profile

Synthetic Microchromosome vector delivery systems

Latest Information Update: 20 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Athersys
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 20 Mar 2007 Discontinued - Preclinical for Undefined in USA (Parenteral)
  • 02 Jul 2002 This technology is still in active development
  • 12 Apr 2000 Preclinical development for Undefined in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top